To learn more about this report, Uncover macros and micros vetted on 75+ parameters: Get instant access to report To learn more about this report, The escalating prevalence of obesity worldwide has emerged as a significant factor propelling the demand for anti-obesity medications
Based on REDEFINE trial populations and the NDA submission terms, expected eligibility criteria are: BMI 30 , or BMI 27 with at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea Adults 18 years or older Not pregnant or breastfeeding Contraindications will likely include: personal or family history of MTC or MEN 2 syndrome, prior serious allergic reaction to semaglutide or cagrilintide, and active pancreatitis
Without adjustments in activity or nutrition, weight loss slows or stops
Join the countless success stories and embark on a journey to a healthier, happier you